AbbVie inks $1.9B deal with IGI for myeloma drug ISB 2001, a promising trispecific antibody with potential to deliver deeper, more durable responses in immuno-oncology.
Pro-Palestinian activist Mahmoud Khalil files $20M claim against Trump administration for false imprisonment and retaliation over his activism.
AbbVie inks $1.9B deal with IGI for myeloma drug ISB 2001, a promising trispecific antibody with potential to deliver deeper, more durable responses in immuno-oncology.
Pro-Palestinian activist Mahmoud Khalil files $20M claim against Trump administration for false imprisonment and retaliation over his activism.